Research Linking Hemorrhages With Drug May Lend Support To Xarelto Lawsuit Plaintiff Claims

July 05, 2016 – – TheProductLawyers.com announces research that could lend support to claims against Xarelto and its manufacturers, Janssen Pharmaceuticals (a division of Johnson & Johnson) and Bayer AG. An apparent link between the risk for spontaneous catastrophic bleeding and the use of the drug prompts ever-mounting concern from the public.

The new-generation anticoagulant received FDA approval in 2011. Initially, it was warmly embraced as a breakthrough in clot prevention. Approved uses included clot prevention for those with pulmonary embolism, deep vein thrombosis, and individuals recovering from replacement surgery on knees or hips. Additionally, the drug was approved as a stroke preventative in individuals with atrial fibrillation.

Soon after, adverse event reports claiming a link between the drug and strokes, clots, massive pulmonary embolisms, and uncontrollable internal and external hemorrhages began accumulating. Doctors John C. Hwang and Judy H. Hun, having prescribed the drug to patients in their care, conducted a study of their own patients.

They noted that at least three of their patients taking Xarelto had developed “spontaneous vitreous hemorrhage” or eye bleeding. Examination of patient histories revealed that the risk for this type of bleeding was most prevalent among individuals who had switched from a more traditional blood thinner, such as warfarin, to the new anticoagulant.

Another study of the longitudinal variety drew data from patients across the United States and compared Xarelto, Pradaxa, and warfarin. Collecting patient histories from more than 46,000 individuals using anticoagulants —39,607 warfarin; 4,907 Pradaxa; 1,649 Xarelto—a trend emerged that suggested a link between dangerous risk of bleeding and the new drug. There was, it was noted, “as much as a 50 percent increase in the risk of gastrointestinal bleeding with dabigatran compared with warfarin or a twofold higher risk of bleeding with rivaroxaban (Xarelto) when compared with warfarin.”

In late 2015, the U.S. Judicial Panel on Multidistrict Litigation combined more than 2,800 lawsuits with similar claims against Xarelto to form MDL No. 2592. The cases for the mass litigation will be tried in the Eastern District of Louisiana under Judge Eldon Fallon. Additional cases with similar claims will be incorporated into the MDL as the cases await trial.

The attorneys of Banville Law, the firm behind TheProductLawyers.com, are offering complimentary consultations to anyone who suffered injury or hospitalization after a bleed while on Xarelto. For more information about this release or the Xarelto litigation call 888-997-3792.

###

Contact TheProductLawyers.com:

Banville Law
888-997-3792
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60011203